Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
17 January, 2019 06:52 IST
Dr. Reddy's Lab gets EIR from USFDA for Hyderabad facility
Source: IRIS | 12 Dec, 2017, 09.50AM
Comments  |  Post Comment

Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the US Food & Drug Administration (USFDA) for its Formulations Manufacturing Plant-3 at Bachupally, Hyderabad as closure of audit.

Earlier in April, USFDA had inspected the Formulations Manufacturing Plant-3 wherein it had issued a form 483 with 11 observations.

The stock had underperformed the market over the past one month till Dec. 11, 2017, falling 6.84% compared with the Sensex's 0.42% rise. It underperformed the market in past one quarter, gaining 1.22% as against 4.94% rise in the Sensex.

Shares of the company gained Rs 88.45, or 4.03%, to trade at Rs 2,281.95. The total volume of shares traded was 41,519 at the BSE (9.39 a.m., Tuesday).

Dr Reddy`S Laboratories Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Suven Life Sciences secures 2 overseas product patents - 16-Jan-2019 13:45
Texmaco Rail & Engineering receives orders worth Rs 2.62 bn - 16-Jan-2019 12:59
Dr Reddy's announces completion of USFDA audit of formulation facility - 16-Jan-2019 10:15
L&T Hydrocarbon consortium wins EPCI order from Saudi Aramco - 15-Jan-2019 10:24
Zydus Cadila gets final approval from USFDA for 2 drugs - 15-Jan-2019 10:20
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer